+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Familial Adenomatous Polyposis Treatment Market - Global Forecast 2026-2030- Product Image
Familial Adenomatous Polyposis Treatment Market - Global Forecast 2026-2030- Product Image
New

Familial Adenomatous Polyposis Treatment Market - Global Forecast 2026-2030

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967598
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Familial Adenomatous Polyposis Treatment Market is undergoing significant change, with technology-driven advancements, evolving regulatory frameworks, and growing patient-centered care initiatives influencing new opportunities and investment priorities for healthcare leaders.

Market Snapshot: Familial Adenomatous Polyposis Treatment Market Growth and Outlook

Currently, the Familial Adenomatous Polyposis Treatment Market stands as a dynamic industry, growing from USD 1.20 billion in 2024 to an anticipated USD 1.29 billion in 2025 and is projected to climb to USD 1.86 billion by 2030, reflecting a robust CAGR of 7.47%. This market is shaped by new therapies and diagnostic advancements, providing a foundation for expanded patient access and improved care pathways.

Scope & Segmentation of the Familial Adenomatous Polyposis Treatment Market

  • Treatment Modalities: Combination therapies integrate endoscopic techniques with pharmaceuticals, offering tailored interventions for diverse polyp burdens and individualized patient requirements.
  • Surveillance Technologies: The adoption of advanced imaging and artificial intelligence in colonoscopy and sigmoidoscopy improves lesion detection, diagnostic accuracy, and patient comfort.
  • Pharmacologic Solutions: Biologics, monoclonal antibodies, gene-based interventions, COX-2 inhibitors, and nonselective NSAIDs enable precise management of disease variability.
  • Surgical Approaches: Procedures such as colectomy, ileorectal anastomosis, and proctocolectomy are chosen based on disease progression and patient preferences.
  • Route of Administration: Intravenous, oral, and subcutaneous formulations ensure therapy flexibility, accommodating disease stage, patient compliance, and logistical needs.
  • Distribution Channels: Hospital pharmacies, online platforms, and retail outlets enable broad therapy access while supporting continuity of care.
  • End User Environments: Management of the condition is delivered across home care, inpatient hospital, and specialty clinic settings, reflecting evolving healthcare strategies.
  • Patient Indications: Both classic and attenuated forms are addressed, recognizing variations in clinical presentation and guiding informed therapy selection.
  • Geographical Regions: The Americas, Europe, Middle East and Africa, and Asia Pacific feature market growth influenced by regulatory policy, infrastructure maturity, and payer systems, impacting both adoption pace and access.

Key Takeaways for Senior Decision-Makers

  • Adoption of digital imaging and artificial intelligence is streamlining surveillance, optimizing clinical workflow, and minimizing invasive procedure frequency.
  • Gene therapy and targeted biologics are reshaping treatment paradigms, supporting durable outcome improvements for high-risk cohorts.
  • Telehealth and digital monitoring platforms enable real-time care adjustments, particularly benefitting geographically dispersed patients and facilitating integrated care models.
  • Strategic collaborations among pharmaceutical firms, biotech innovators, and contract manufacturers are reinforcing resilience in therapeutic pipelines and ensuring consistent market supply.
  • Institutions are evolving market access approaches, including refreshed rebate arrangements and partnerships with advocacy groups to enhance treatment equity.
  • Industry consolidation through mergers and partnerships is expanding global capabilities and supporting rapid innovation cycles for emergent therapies.

Tariff Impact on Supply Chain and Market Access

Recent tariffs imposed by the United States on imported pharmaceutical ingredients and drugs are shifting supply chain strategies within the familial adenomatous polyposis treatment sector. These measures are prompting manufacturers to increase domestic sourcing and reevaluate procurement policies, impacting operational costs and research budgets with particular effects on smaller entities. Industry stakeholders are engaging in local manufacturing initiatives, negotiating favorable trade terms, and pursuing collective action to achieve tariff relief. As market participants adjust to price dynamics, robust supply chain risk management is central to sustaining therapy access and minimizing disruptions in patient care.

Methodology & Data Sources Used in This Market Analysis

This market analysis integrates comprehensive secondary research, covering published literature, regulatory guidance, clinical trials, and intellectual property records, with primary research involving direct interviews with key stakeholders. Data robustness is ensured through triangulation, expert review sessions, and collaborative stakeholder workshops conducted throughout the assessment process.

Why This Report Matters for Healthcare Strategists

  • Delivers segmented, executive-level insight to support investment, partnership, and expansion decisions in the Familial Adenomatous Polyposis Treatment Market.
  • Enables organizations to identify vulnerabilities in supply chains, assess technological adoption, and evaluate regional opportunities for growth and patient access strategies.
  • Equips leadership with actionable recommendations for strategic planning in areas such as market access frameworks, reimbursement environment, and the innovation life cycle.

Conclusion

Familial Adenomatous Polyposis Treatment Market trends highlight the importance of aligning organizational strategy with regulatory changes and technological advances. Senior decision-makers can use this analysis to support resilient patient care and pursue sustainable growth in a dynamic market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Familial Adenomatous Polyposis Treatment Market, by Treatment Type
8.1. Combination Therapy
8.2. Endoscopic Surveillance
8.2.1. Colonoscopy
8.2.2. Sigmoidoscopy
8.3. Pharmacologic Therapy
8.3.1. Biologics
8.3.1.1. Gene Therapy
8.3.1.2. Monoclonal Antibodies
8.3.2. Nonsteroidal Anti-Inflammatory Drugs
8.3.2.1. COX-2 Inhibitors
8.3.2.2. Nonselective NSAIDs
8.4. Surgical Intervention
8.4.1. Colectomy
8.4.2. Ileorectal Anastomosis
8.4.3. Proctocolectomy
9. Familial Adenomatous Polyposis Treatment Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Familial Adenomatous Polyposis Treatment Market, by End User
11.1. Home Care
11.2. Hospitals
11.3. Specialty Clinics
12. Familial Adenomatous Polyposis Treatment Market, by Indication
12.1. Attenuated FAP
12.2. Classic FAP
13. Familial Adenomatous Polyposis Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Familial Adenomatous Polyposis Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Familial Adenomatous Polyposis Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Familial Adenomatous Polyposis Treatment Market
17. China Familial Adenomatous Polyposis Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2024
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2024
18.3. Product Portfolio Analysis, 2024
18.4. Benchmarking Analysis, 2024
18.5. Bayer Corporation
18.6. Biodexa Pharmaceuticals PLC
18.7. Boston Scientific Corporation
18.8. Eloxx Pharmaceuticals, Inc.
18.9. Emtora Biosciences
18.10. FUJIFILM Holdings Corporation
18.11. KD Pharma Group
18.12. Medtronic plc
18.13. Olympus Corporation
18.14. Parabilis Medicines
18.15. Pentax Ricoh Imaging Company, Ltd.
18.16. Siemens Healthcare Private Limited
18.17. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 12. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 13. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
List of Tables
TABLE 1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
TABLE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 31. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 32. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 33. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 34. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 35. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 36. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 37. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 38. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 39. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 40. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 41. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 42. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 43. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 44. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 45. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 46. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 47. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 48. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 49. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 50. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 51. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 52. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 53. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 54. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 55. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 56. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 57. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 58. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 59. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 60. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 61. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 62. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 63. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 64. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 65. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 66. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 67. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 68. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 69. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 70. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 71. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 72. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 73. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 74. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 75. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 76. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 77. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 78. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 79. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 80. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 81. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 82. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 83. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 84. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 85. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 86. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 87. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 88. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 89. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 90. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 91. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
TABLE 92. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 93. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 94. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 95. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 96. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 97. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 98. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 99. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 100. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 101. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 102. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 103. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 104. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 105. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 106. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 107. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 108. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 109. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 110. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 111. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 112. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 113. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 114. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 115. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 116. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 117. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 118. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 119. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 120. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 121. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 122. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 123. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 135. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 136. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 137. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 138. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 139. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 140. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 141. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 142. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 143. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 144. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 145. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 146. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 147. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 148. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 149. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 150. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 151. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 152. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 153. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 154. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 155. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 156. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 157. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 158. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 159. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 160. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 161. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 162. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 163. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 164. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 165. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 166. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 167. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 168. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 169. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 170. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 171. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 172. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 173. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 174. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 175. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 176. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 177. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 178. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 179. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2030 (USD THOUSAND)
TABLE 180. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 181. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 182. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 183. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 184. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 185. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 186. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 187. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 188. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 189. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 190. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 191. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 192. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 193. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 194. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 195. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 196. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 197. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 198. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 199. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 200. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 201. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 202. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 203. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 204. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 205. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 206. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 207. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 208. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 209. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 210. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 211. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 212. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 213. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 214. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 215. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 216. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 217. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 218. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 219. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 220. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 221. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 222. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 223. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 224. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 225. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 226. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 227. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 228. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 229. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 230. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 231. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 232. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 233. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 234. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 235. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 236. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 237. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 238. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 239. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 240. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 241. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 242. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 243. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 244. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 245. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 246. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 247. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
TABLE 248. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 249. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 250. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 251. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 252. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 253. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 254. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
TABLE 255. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
TABLE 256. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 257. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
TABLE 258. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
TABLE 259. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
TABLE 260. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
TABLE 261. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
TABLE 262. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
TABLE 263. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
TABLE 264. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
TABLE 265. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUS

Companies Mentioned

The key companies profiled in this Familial Adenomatous Polyposis Treatment market report include:
  • 23andMe, Inc.
  • Ambry Genetics Corporation by Tempus Company
  • Bayer Corporation
  • Beckman Coulter, Inc.
  • BGI Genomics Co., Ltd.
  • Biodexa Pharmaceuticals PLC
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical LLC
  • Eiken Chemical Co., Ltd.
  • Eloxx Pharmaceuticals, Inc.
  • Emtora Biosciences
  • FUJIFILM Holdings Corporation
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • KD Pharma Group
  • Labcorp Holdings Inc.
  • Medtronic plc
  • Myriad Genetics, Inc.
  • Olympus Corporation
  • Panbela Therapeutics, Inc.
  • Parabilis Medicines
  • Pentax Ricoh Imaging Company, Ltd.
  • PreventionGenetics
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Recursion Pharmaceuticals, Inc.
  • SENTINEL CH. SpA
  • Siemens Healthcare Private Limited
  • Stryker Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.86 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Familial Adenomatous Polyposis - Pipeline Insight, 2025 - Product Image

Familial Adenomatous Polyposis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Familial Adenomatous Polyposis Pipeline Analysis Report 2025 - Product Image

Familial Adenomatous Polyposis Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From
Gardner Syndrome Treatment Market Report 2025 - Product Image

Gardner Syndrome Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Colorectal Cancer Diagnosis and Therapeutic Updates - Product Image

Colorectal Cancer Diagnosis and Therapeutic Updates

  • Book

About the Familial Adenomatous Polyposis Drug Market

Familial Adenomatous Polyposis (FAP) is a rare genetic disorder that causes the formation of numerous polyps in the colon. These polyps can become cancerous if left untreated. As such, drugs used to treat FAP are important in the treatment of colon cancer. These drugs are typically targeted therapies, which are designed to specifically target the genetic mutation that causes FAP. Commonly used drugs include bevacizumab, cetuximab, and panitumumab. These drugs are used in combination with other treatments such as chemotherapy and radiation therapy. The Familial Adenomatous Polyposis Drug market is a small but growing market. It is driven by the increasing prevalence of FAP and the need for effective treatments. The market is expected to grow in the coming years as new treatments are developed and approved. Some companies in the market include Roche, Merck, Pfizer, and Bristol-Myers Squibb. These companies are involved in the development and marketing of drugs used to treat FAP. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.